Amphastar Pharmaceuticals, Inc. $AMPH Shares Purchased by LSV Asset Management

LSV Asset Management boosted its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 50.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 110,300 shares of the company’s stock after acquiring an additional 37,000 shares during the quarter. LSV Asset Management owned 0.24% of Amphastar Pharmaceuticals worth $2,954,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. FNY Investment Advisers LLC acquired a new position in Amphastar Pharmaceuticals in the third quarter valued at $26,000. Quarry LP acquired a new position in Amphastar Pharmaceuticals in the third quarter valued at $32,000. Farther Finance Advisors LLC boosted its holdings in Amphastar Pharmaceuticals by 46.3% in the fourth quarter. Farther Finance Advisors LLC now owns 1,381 shares of the company’s stock valued at $37,000 after acquiring an additional 437 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Amphastar Pharmaceuticals by 37.8% in the fourth quarter. GAMMA Investing LLC now owns 1,685 shares of the company’s stock valued at $45,000 after acquiring an additional 462 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Amphastar Pharmaceuticals by 24.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,233 shares of the company’s stock valued at $60,000 after acquiring an additional 435 shares during the last quarter. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Trading Up 2.2%

Shares of AMPH opened at $18.81 on Wednesday. The stock’s 50-day moving average is $20.11 and its two-hundred day moving average is $23.97. The stock has a market cap of $829.39 million, a PE ratio of 11.33, a P/E/G ratio of 2.98 and a beta of 0.97. Amphastar Pharmaceuticals, Inc. has a 12 month low of $16.65 and a 12 month high of $31.26. The company has a debt-to-equity ratio of 0.79, a current ratio of 3.85 and a quick ratio of 2.82.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.28). The company had revenue of $171.17 million for the quarter, compared to analyst estimates of $173.46 million. Amphastar Pharmaceuticals had a return on equity of 15.12% and a net margin of 11.00%. Equities analysts forecast that Amphastar Pharmaceuticals, Inc. will post 2.93 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

AMPH has been the topic of a number of research analyst reports. Jefferies Financial Group reiterated a “hold” rating and issued a $22.00 target price (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Tuesday, April 21st. Weiss Ratings cut Amphastar Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, April 10th. Piper Sandler restated a “neutral” rating and set a $21.00 price objective (down from $25.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 11th. Wells Fargo & Company restated an “equal weight” rating and set a $19.00 price objective (down from $30.00) on shares of Amphastar Pharmaceuticals in a research note on Thursday, May 14th. Finally, Barclays reduced their price objective on Amphastar Pharmaceuticals from $30.00 to $23.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 8th. Seven investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Amphastar Pharmaceuticals currently has an average rating of “Reduce” and an average target price of $24.50.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.